anti glp 1 drugs FDA says that the GLP-1 shortage is over The anti-inflammatory feature of glucagon-like
Description
Tirzepatide-induced injection site reaction

Comparative Effectiveness Analysis Recent meta-analyses have provided insights into the relative effectiveness of different GLP-1 agonists

Cost-effectiveness analyses of antihypertensive medicines: A systematic review

Diabetes Ther (2015) 6(1):2940

The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect

This promotes the use of GLP-1 agonists for treating diabetes
